4.22 million American adults have glaucoma, and the United States trains somewhere between 75 and 95 glaucoma fellows a year to care for all of them.

Read those 2 numbers together and the imbalance gets hard to ignore, because 1 year of graduates couldn't staff a single large health system. There's no surge capacity behind them, no reserve of glaucoma surgeons waiting somewhere to be activated, and no way to manufacture more on short notice. The pipeline has been roughly this size for a decade while the patient population grew every year, and every one of those fellows will have multiple offers before they finish.

Which raises the question this article exists to ask. Why do surgeons this scarce negotiate like they're replaceable?

Why Glaucoma Demand Outruns Every Ophthalmology Subspecialty

That prevalence figure comes from a 2024 study in JAMA Ophthalmology, which put it at 2.56% of everyone over 40, and the CDC has since adopted it as the primary national estimate. Because glaucoma is overwhelmingly a disease of people past 60, and because that's the fastest growing segment of the country, the number only moves one direction.

Surgical volume tells the same story with more force. Medicare Part B data shows glaucoma procedures rose 177% in a single decade, from 80,151 in 2011 to 221,602 in 2021, while Medicare payment for those procedures went from $71.5 million to $246.1 million. The mix shifted underneath that growth, with trabeculectomy falling 58.5% while MIGS grew roughly 20 times over, and the total workload still nearly tripled in 10 years.

There's a detail buried in that shift that should interest anyone who trained recently, which is that trabeculectomy exposure in fellowship dropped 55.9% between 2016 and 2024. The field is producing surgeons with less experience in the one procedure that reliably drives pressure into single digits, at exactly the moment the disease burden is expanding, so a surgeon who trained with real trabeculectomy volume holds something the market is quietly running out of and almost nobody has explained what it's worth.

Where Ophthalmology's Glaucoma Surgeons Stopped Practicing

A 2025 study in JAMA Ophthalmology mapped where ophthalmic surgical subspecialists actually practice, using Medicare data across 13,526 subspecialists and 1.6 million patients, and found that 17.4% of patients live rurally while only 5.6% of surgeons do.

For glaucoma the finding was worse, with the rural share of glaucoma surgeons falling 3.3 percentage points over the study period. That's the steepest rural decline of any ophthalmic subspecialty, against 1.3 points for cornea and 0.4 for retina, which means glaucoma surgeons have been actively withdrawing from everywhere that isn't a metro rather than merely spreading thin across it.

The lived version shows up in a drive time study published in Ophthalmology Glaucoma, where median county-level drive time to the nearest glaucoma specialist runs about 10 minutes in Connecticut and Massachusetts, 4 hours and 24 minutes in North Dakota, and 2 hours and 35 minutes in South Dakota. A separate Florida analysis found roughly 1 in 9 Floridians over 65, about 438,000 people, living more than an hour from a glaucoma specialist.

That's usually framed as an access crisis, and it's one. Viewed from the other side of the table it's also a map of leverage, because every county where the drive is measured in hours is a market where a glaucoma trained surgeon is the option rather than one option among several.

The Ophthalmology Market Already Priced Your Scarcity

In the most recent fellowship match, glaucoma left only 11 positions unfilled, against 14 in cornea and 28 in retina, making it the most competitive of the 3 major fellowships with applicant interest at its highest recorded level. The people choosing careers can see where demand is heading.

Employers see it too, and they've adjusted. Recruiters who specialize in ophthalmology report that subspecialist searches routinely run 12 to 18 months, followed by another 3 to 6 months of credentialing before the new surgeon can bill anyone, against 3 to 5 months for an optometrist. A practice that needs a glaucoma surgeon spends 2 years waiting for 1 person to say yes rather than selecting from a field of candidates.

Now consider what that same employer puts in front of the candidate who finally appears. They offer a salary near the published benchmark, a signing bonus, relocation, and a production formula written by someone else, which is a decent package by the standards of employment and gets presented as though the terms were handed down rather than chosen.

And the candidate accepts, because 12 years of training taught them to be evaluated rather than to evaluate. Match lists, rank orders, board scores, and fellowship interviews all condition a physician to hope they're selected, and then one day the leverage flips completely and nobody sends a memo. The scarcest surgeon in the building keeps negotiating like an applicant.

What Leverage Buys an Ophthalmologist Besides Salary

The part that gets missed is that the best use of scarcity is ownership rather than another $40,000 on a base salary, because ownership is where the money in this specialty has always lived.

Think about what a glaucoma practice is as a business. The clinic visits recur for life, since glaucoma doesn't resolve and gets managed until the patient dies, the diagnostics recur on a schedule set by the disease rather than by marketing, the surgical volume grows as the panel ages, and cataract flows out of that same panel. A practice built around a glaucoma surgeon is one of the most predictable annuities in medicine, and the person that annuity depends on is usually the one collecting a W-2 to service it.

An employed glaucoma specialist produces that annuity for someone else, while an owner produces it for himself, keeps what the practice earns after costs, and builds an asset with value beyond the years he personally operates.

There's a second layer that fellows almost never think about, which is what you inherit rather than what you build. A glaucoma practice running for 30 years carries a referral network of optometrists and comprehensive ophthalmologists who've been sending their pressure patients to the same name for a generation, and those relationships took decades to form, are worth more than any equipment in the building, and transfer to a successor who gets introduced properly by the surgeon leaving. Start a practice from scratch in the same town and you'll spend 5 years building what an acquisition hands you on the first day.

That's the asymmetry nobody explains during fellowship. Building is romantic and slow, inheriting is unglamorous and immediate, and inheriting is how most of the wealth in this specialty actually gets made.

The Ophthalmology Offer Nobody Puts in Front of You

Fellows keep taking the first offer because the alternative rarely appears in the room. Hospital systems offer employment, investor-backed platforms offer employment with equity language tied to somebody else's exit, and established groups offer an associate track with a buy in priced several years out and several hundred thousand dollars away.

Nobody stands in front of a graduating glaucoma fellow and says the plain thing, which is that a surgeon this scarce can own a practice outright, starting now, and let the scarcity work for the owner instead of the employer.

That structure does exist. Retiring ophthalmologists all over the country run established, fully booked practices with no successor anywhere in sight, and everything above explains why the buyer line is so short. A fellowship trained glaucoma surgeon willing to look past the same handful of metros everyone else is fighting over can walk into a running practice, own the professional corporation from day one, and inherit a referral base that took 30 years to build.

The training system spent 12 years teaching you to be chosen, while the fill rates, the 2 year search timelines, and the 4 hour drives are all telling you the same thing, which is that the choosing is yours now. The first offer is what employers extend to people they're hoping won't notice, and you're in a position to notice.

Educational material only. Figures are illustrative and individual results vary. Images are AI-generated illustrations and don't depict actual Verdira practices, physicians, or patients. See our Disclosures.